Table 1.
Summary of GBM patients’ clinical data
| Patient characteristics | |||||||
|---|---|---|---|---|---|---|---|
| Sex | Female: 19/37.3% | Male: 32/62.7% | |||||
| Median age at diagnosis | 59 years (range 22 years–78 years) | ||||||
| ECOG at diagnosis | 0: 26/50.9% | 1: 19/37.3% | >1: 6/11.8% | ||||
| Tumor characteristics | |||||||
| Median tumor volume | 24.3 ccm (range 0.22–98.8 ccm) | ||||||
| Tumor localization at diagnosis | Left hemisphere: 28/54.9% | Right hemisphere: 18/35.3% | Both hemispheres: 5/9.8% | ||||
| Tumor localization at diagnosis (lobe) | Frontal: 15/29.4% | Occipital: 6/11.8% | Temporal: 8/15.7% | Parietal: 5/9.8% | Multifocal: 16/31.4% | Others: 1/2% | |
| Relapse/tumor progress | Primarily multifocal: 9/17.6% | Local relapse: 27/52.9% | Multifocal relapse: 15/29.4% | ||||
| IDH1 mutation | WT IDH1: 36/87.8% | IDH1 R132H: 5/12.2% | |||||
| MGMT promoter methylation | Unmethylated: 10/23.8% | Methylated: 32/76.2% | |||||
| Ki67 staining (median) | 25% (range 10%–50%) | ||||||
| Therapy | |||||||
| Time from diagnosis to surgery | 0–7 days: 28/54.9% | 8–14 days: 15/29.4% | >14 days: 8/15.7% | ||||
| Surgical intervention | Biopsy: 9/17.6% | Complete resection: 11/21.6% | Incomplete resection: 30/58.5% | ||||
| Radiation therapy | Yes: 45/93.8% | No: 3/6.3% | |||||
| Adjuvant chemotherapy with TMZ | Yes: 38/80.9% | No: 9/19.1% | |||||
| Outcome results | |||||||
| OS | 0–6 months: 5/9.8% | >6 months: 46/90.2% | |||||
| PFS | 0–6 months: 8/19% | >6 months: 34/81% | |||||
Note: Given are the absolute numbers of the GBM patients in each group and the percentage of the analyzed population.
Abbreviations: ECOG, Eastern Cooperative Oncology Group scale; GBM, glioblastoma; IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; OS, overall survival; PFS, progression-free survival; TMZ, temozolomide; WT, wildtype.